trending Market Intelligence /marketintelligence/en/news-insights/trending/piy1guz8byejrb-lelnghw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Leap Therapeutics prices $14M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Leap Therapeutics prices $14M common stock offering

Leap Therapeutics, Inc. priced an underwritten public offering of 1,866,667 shares at $7.50 apiece to raise about $14 million in gross proceeds.

Raymond James & Associates Inc. and Ladenburg Thalmann are acting as book-running managers for the offering which is expected to close by March 27.

The Cambridge, Mass.-based biopharmaceutical company granted underwriters an option to buy up to an additional 280,000 shares.

The company plans to use the net proceeds for general corporate purposes, which may include funding new clinical trials of DKN-01 and TRX518.

DKN-01 is under development to treat patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers. TRX518 is an antibody designed to enhance the immune system's anti-tumor response.